Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: The DILIPO study

European Journal of Heart Failure

Volumn 13, Issue 3, 2011, Pages 327-336

  Aronson, Doron ^a,b   Verbalis, Joseph G ^c   Mueller, Matthias ^d   Krum, Henry ^e  

^a RAMBAM MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^d SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^e MONASH UNIVERSITY   (Australia)

Author keywords

Congestive heart failure; Hyponatremia; Satavaptan

Indexed keywords

SATAVAPTAN;

AGED; ANEMIA; ANXIETY; ARTICLE; BRONCHITIS; CONGESTIVE HEART FAILURE; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EPISTASIS; FEMALE; FEVER; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPERNATREMIA; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SODIUM BLOOD LEVEL; THIRST; URINARY TRACT INFECTION;

ADULT; AGED; BODY WEIGHT; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE; HUMANS; HYPONATREMIA; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MORPHOLINES; RECEPTORS, VASOPRESSIN; SODIUM; SPIRO COMPOUNDS; TREATMENT OUTCOME; VASOPRESSINS; YOUNG ADULT;

EID: 79951820513     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfq226     Document Type: Article

References (33)

1. Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med 2000;342:1581-1589. (Pubitemid 30340505)
2. Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007;120: S1-S21. (Pubitemid 350027722)
3. Klein L, O'Connor CM, Leimberger JD, Gattis-Stough W, Pina IL, Felker GM, Adams KF Jr, Califf RM, Gheorghiade M. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Mil-rinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 2005;111:2454-2460. (Pubitemid 40696133)
4. Gheorghiade M, Abraham WT, Albert NM, Gattis Stough W, Greenberg BH, O'Connor CM, She L, Yancy CW, Young J, Fonarow GC. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J 2007;28:980-988. (Pubitemid 47343897)
5. Barsheshet A, Shotan A, Cohen E, Garty M, Goldenberg I, Sandach A, Behar S, Zimlichman E, Lewis BS, Gottlieb S. Predictors of long-term (4-year) mortality in elderly and young patients with acute heart failure. Eur J Heart Fail 2010;12: 833-840.
6. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007;297:1332-1343. (Pubitemid 46513234)
7. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007;297:1319-1331. (Pubitemid 46513233)
8. Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet D, Berl T, Schrier RW. Radio-immunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 1981;305:263-266. (Pubitemid 11087371)
9. Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 1986;73:257-267. (Pubitemid 16127402)
10. Lilly LS, Dzau VJ, Williams GH, Rydstedt L, Hollenberg NK. Hyponatremia in congestive heart failure: implications for neurohumoral activation and responses to orthostasis. J Clin Endocrinol Metab 1984;59:924-930. (Pubitemid 14020694)
11. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol 2005;46:1785-1791. (Pubitemid 41579797)
12. Goldsmith SR. Current treatments and novel pharmacologic treatments for hypo-natremia in congestive heart failure. Am J Cardiol 2005;95:14-23.
13. Packer M, Medina N, Yushak M. Relation between serum sodium concentration and the hemodynamic and clinical responses to converting enzyme inhibition with captopril in severe heart failure. J Am Coll Cardiol 1984;3:1035-1043. (Pubitemid 14171221)
14. Dunlay SM, Gheorghiade M, Reid KJ, Allen LA, Chan PS, Hauptman PJ, Zannad F, Maggioni AP, Swedberg K, Konstam MA, Spertus JA. Critical elements of clinical follow-up after hospital discharge for heart failure: insights from the EVEREST trial. Eur J Heart Fail 2010;12:367-374.
15. Yeates KE, Morton AR. Vasopressin antagonists: role in the management of hypo-natremia. Am J Nephrol 2006;26:348-355. (Pubitemid 44394153)
16. Rai A, Whaley-Connell A, McFarlane S, Sowers JR. Hyponatremia, arginine vaso-pressin dysregulation, and vasopressin receptor antagonism. Am J Nephrol 2006; 26:579-589. (Pubitemid 46143880)
17. Serradeil-Le Gal C, Lacour C, Valette G, Garcia G, Foulon L, Galindo G, Bankir L, Pouzet B, Guillon G, Barberis C, Chicot D, Jard S, Vilain P, Garcia C, Marty E, Raufaste D, Brossard G, Nisato D, Maffrand JP, Le Fur G. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest 1996;98:2729-2738. (Pubitemid 26427399)
18. Soupart A, Gross P, Legros JJ, Alfoldi S, Annane D, Heshmati HM, Decaux G. Successful long-term treatment of hyponatremia in syndrome of inappropriate anti-diuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin J Am Soc Nephrol 2006;1: 1154-1160.
19. Gines P, Wong F, Watson H, Milutinovic S, Ruiz Del Arbol L, Olteanu D. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia. A randomized trial. Hepatology 2008;48:204-213. (Pubitemid 351975545)
20. Verbalis JG. Whole-body volume regulation and escape from antidiuresis. Am J Med 2006;119:S21-S29. (Pubitemid 44026590)
21. Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet 2008;371:1624-1632. (Pubitemid 351626846)
22. Packer M, Lee WH, Kessler PD, Medina N, Yushak M, Gottlieb SS. Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure. J Am Coll Cardiol 1987;10:837-844. (Pubitemid 17163109)
23. Mettauer B, Rouleau JL, Bichet D, Juneau C, Kortas C, Barjon JN, de Champlain J. Sodium and water excretion abnormalities in congestive heart failure. Determinant factors and clinical implications. Ann Intern Med 1986;105:161-167. (Pubitemid 16039286)
24. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, Kubo SH, Rudin-Toretsky E, Yusuf S. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A sub-study of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82: 1724-1729. (Pubitemid 20367975)
25. Kazory A. Haemodialysis, not ultrafiltration, can correct hyponatraemia in heart failure. Eur J Heart Fail 2010;12:208.
26. Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, Orlandi C. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003;107:2690-2696. (Pubitemid 36667242)
27. Gheorghiade M, Gattis WA, O'Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004;291: 1963-1971. (Pubitemid 38544277)
28. Ghali JK, Koren MJ, Taylor JR, Brooks-Asplund E, Fan K, Long WA, Smith N. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 2006;91:2145-2152. (Pubitemid 43854997)
29. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099-2112. (Pubitemid 44749318)
30. Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol 2007;27:447-457. (Pubitemid 47482001)
31. Decaux G, Soupart A. Treatment of symptomatic hyponatremia. Am J Med Sci 2003;326:25-30. (Pubitemid 36870294)
32. Sterns RH, Silver SM. Brain volume regulation in response to hypo-osmolality and its correction. Am J Med 2006;119:S12-S16.
33. Gerbes AL, Gulberg V, Gines P, Decaux G, Gross P, Gandjini H, Djian J. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003;124:933-939. (Pubitemid 36389796)